CL2021000924A1 - Use of reboxetine for the treatment of narcolepsy - Google Patents
Use of reboxetine for the treatment of narcolepsyInfo
- Publication number
- CL2021000924A1 CL2021000924A1 CL2021000924A CL2021000924A CL2021000924A1 CL 2021000924 A1 CL2021000924 A1 CL 2021000924A1 CL 2021000924 A CL2021000924 A CL 2021000924A CL 2021000924 A CL2021000924 A CL 2021000924A CL 2021000924 A1 CL2021000924 A1 CL 2021000924A1
- Authority
- CL
- Chile
- Prior art keywords
- narcolepsy
- reboxetine
- treatment
- cataplexy
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Abstract
En la presente se describen métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.Described herein are methods for the treatment of cataplexy narcolepsy, which comprise administering reboxetine to a human in need thereof. Reboxetine can also be used in the manufacture of a drug for the treatment of narcolepsy with cataplexy. Also described herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions for using the pharmaceutical composition to treat cataplexy narcolepsy in a human.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862745956P | 2018-10-15 | 2018-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000924A1 true CL2021000924A1 (en) | 2021-09-03 |
Family
ID=70284075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000924A CL2021000924A1 (en) | 2018-10-15 | 2021-04-14 | Use of reboxetine for the treatment of narcolepsy |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3866768A4 (en) |
JP (1) | JP2022504975A (en) |
KR (1) | KR20210071046A (en) |
CN (1) | CN112888430A (en) |
AU (2) | AU2019361915A1 (en) |
BR (1) | BR112021007019A2 (en) |
CA (1) | CA3115983A1 (en) |
CL (1) | CL2021000924A1 (en) |
CO (1) | CO2021004681A2 (en) |
CR (1) | CR20210514A (en) |
EC (1) | ECSP21031200A (en) |
IL (1) | IL282311A (en) |
MX (1) | MX2021004207A (en) |
PE (1) | PE20211199A1 (en) |
SG (1) | SG11202103588WA (en) |
WO (1) | WO2020081461A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
KR20230055668A (en) * | 2021-10-19 | 2023-04-26 | 단국대학교 천안캠퍼스 산학협력단 | Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
EP1763354A2 (en) * | 2004-06-09 | 2007-03-21 | Pfizer Limited | Use of reboxetine for the treatment of pain |
PT2968208T (en) * | 2013-03-13 | 2022-10-28 | Aerial Biopharma Llc | Treatment of cataplexy |
-
2019
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/en active Pending
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/en unknown
- 2019-10-14 CR CR20210514A patent/CR20210514A/en unknown
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/en active Pending
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/en unknown
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en unknown
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/en not_active Application Discontinuation
- 2019-10-14 CA CA3115983A patent/CA3115983A1/en active Pending
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/en unknown
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
-
2021
- 2021-04-13 IL IL282311A patent/IL282311A/en unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/en unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/en unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/en unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20210514A (en) | 2021-11-12 |
IL282311A (en) | 2021-05-31 |
PE20211199A1 (en) | 2021-07-01 |
AU2019361915A1 (en) | 2021-05-13 |
KR20210071046A (en) | 2021-06-15 |
JP2022504975A (en) | 2022-01-13 |
MX2021004207A (en) | 2021-08-11 |
EP3866768A1 (en) | 2021-08-25 |
CO2021004681A2 (en) | 2021-06-21 |
BR112021007019A2 (en) | 2021-07-13 |
EP3866768A4 (en) | 2022-01-05 |
CN112888430A (en) | 2021-06-01 |
WO2020081461A1 (en) | 2020-04-23 |
AU2023200917A1 (en) | 2023-03-23 |
SG11202103588WA (en) | 2021-05-28 |
ECSP21031200A (en) | 2021-05-31 |
CA3115983A1 (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000924A1 (en) | Use of reboxetine for the treatment of narcolepsy | |
DOP2023000187A (en) | ANTIBODIES TARGETTING HIV GP120 AND METHODS OF USE | |
DOP2019000180A (en) | INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME | |
CL2017002996A1 (en) | Tetra-substituted alkene compounds and their use | |
CL2022001743A1 (en) | Gamma-Hydroxybutyrate (GHB) Dosage | |
BR112016027773A2 (en) | cell penetrating peptide, polynucleotide, recombinant botulinum toxin penetrating cell protein, recombinant expression vector, bacterium, pharmaceutical composition, cosmetic composition and method for producing a recombinant botulinum toxin cell penetrating protein | |
CL2008001268A1 (en) | Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain. | |
CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
CO2020009670A2 (en) | Compositions comprising the co-selected microbiota and methods for their use | |
CO2021015793A2 (en) | Methods of treating or preventing asthma by administering an il-33 antagonist | |
BR112017006113A8 (en) | Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits. | |
BR112023005160A2 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
MX2020004513A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
BR112019004540A2 (en) | method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin | |
CL2022001079A1 (en) | Methods and compositions for the treatment of rett syndrome | |
BR112019001082A2 (en) | levodopa and carbidopa intestinal gel and methods of use | |
CL2021003442A1 (en) | Pharmaceutical composition comprising idelalisib and defactinib; and methods for treating cancer. | |
AR122344A1 (en) | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS | |
UY39257A (en) | AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND ITS USE | |
CL2022001476A1 (en) | Use of reboxetine to treat disorders of the nervous system | |
PE20230181A1 (en) | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS | |
CL2019003288A1 (en) | A pharmaceutical combination for the treatment of cancer. | |
BR112018014771A2 (en) | composition comprising algal proteoglycan extract and its use | |
AR112535A1 (en) | METHODS FOR THE TREATMENT OF TNFa-RELATED DISEASES | |
CL2023002236A1 (en) | Methods to treat primary amyloidosis |